DR LINDEN: What we’ve all been excited about is the idea of offering a patient an alternative to cytotoxic therapy. Because it’s not just people who’ve had bad experiences or people with neighbors who’ve had bad experiences with chemotherapy. Chemotherapy is more fatiguing to people. And so I think we’re all looking for answers, and I think inhibiting that proliferative pathway is a very exciting direction.
DR LOVE: Can you go through the design of the BOLERO-2 study?
DR LINDEN: So this was for people who had progressed on what is our first-line line therapy, an AI, and had metastatic disease. And those are the people who many of us would give systemic chemotherapy to. So it was good design. The patients were randomized to either get exemestane, the steroidal aromatase inhibitor, or get the mTOR inhibitor in a big dose with the same AI. There’s a clear benefit to patients that kind of looks like you were giving them chemotherapy.